Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Employees - 112,
CEO - Ram Aiyar MBA,,
Sector - Healthcare,
Country - US,
Market Cap -
Altman ZScore(max is 10): -1.69, Piotroski Score(max is 10): 3, Working Capital: $85461000, Total Assets: $180425000, Retained Earnings: $-315743000, EBIT: -99754000, Total Liabilities: $65322000, Revenue: $6281000
AryaFin Target Price - $1.04 - Current Price $ - Analyst Target Price $
| Ticker | KRRO |
| Index | |
| Curent Price | |
| Change | |
| Market Cap | |
| Average Volume | |
| Income | |
| Sales | |
| Book Value/Share | |
| Cash/Share | |
| Dividend Est | |
| Dividend TTM | |
| Dividend Ex-Date | |
| Employees | |
| Moving Avg 20days | |
| Moving Avg 50days | |
| Moving Avg 200days | |
| Shares Outstanding | |
| Earnings Date | |
| Inst. Ownership |
| Price/Earnings | |
| Forwad P/E | |
| PE Growth | |
| Price/Sales | |
| Price/Book | |
| Price/Cash | |
| Price/FCF | |
| Quick Ratio | |
| Current Ratio | |
| Debt/Equity | |
| Return on Assets | |
| Return on Equity | |
| Return on Investment | |
| Gross Margin | |
| Ops Margin | |
| Profit Margin | |
| RSI | |
| BETA(β) | |
| From 52week Low | |
| From 52week High |
| EPS | |
| EPS next Year | |
| EPS next Qtr | |
| EPS this Year | |
| EPS next 5 Year | |
| EPS past 5 Year | |
| Sales past 5 Year | |
| EPS Y/Y | |
| Sales Y/Y | |
| EPS Q/Q | |
| Sales Q/Q | |
| Sales Surprise | |
| EPS Surprise | |
| ATR(14) | |
| Perf Week | |
| Perf Month | |
| Perf Quarter | |
| Perf Year | |
| Perf YTD | |
| Target Price |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer